Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
about
Hyperuricaemia with deposition: latest evidence and therapeutic approachA review of uric acid, crystal deposition disease, and gout.Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipientsImpact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsAn old disease with new insights: Update on diagnosis and treatment of gout.Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout.Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.Population-specific association between ABCG2 variants and tophaceous disease in people with goutPharmacokinetics considerations for gout treatments.The gouty tophus: a review.Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout.Illness Perceptions and Mortality in Patients With Gout: A Prospective Observational Study.Impact of allopurinol on risk of myocardial infarction.Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).Digital tomosynthesis as a new diagnostic tool for assessing of chronic gout arthritic feet and ankles: comparison of plain radiography and computed tomography.Ulcerated tophaceous gout.An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study.Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.Increased platelet reactivity as measured by plasma glycoprotein VI in gout.Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout.Treat to target in gout.Cardiac and renal protective effects of urate-lowering therapy.Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography.Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient.Improving adherence to gout therapy: an expert review.Gout treatment—more tablets might be neededAssociation of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery DiseaseMonosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare
P2860
Q26775759-370AD4BE-6F49-4007-87FD-3BA409647D62Q30619265-AB02BC3C-5699-49C1-86B1-66DF2B9E5A64Q33766720-A8E6368B-93A0-4404-9F5E-753865B28C37Q33864537-7EB2CBEC-385C-455F-B6B1-229DDD483ABCQ34542091-A3A2E715-7BF2-4FAE-8F0D-0EADE99209EBQ35073601-903B5F71-2159-42A1-AAA7-8D26E8CDBCFFQ36225590-8926DF54-92D9-428D-84CA-406311F4A9D4Q36233048-0FC72F39-43EF-452F-B54E-8D65DC1CDB67Q37080656-62985E2D-7CB8-4EBA-8937-FA4FDF9068C1Q37686521-09E9A8A3-EF18-454D-BD70-F05C9F77D774Q38210284-D21D5A93-CF53-47CF-A776-FF559FD37254Q38374318-63F2CB31-07AD-494E-B68D-9ADA0F54F581Q38426602-160FB3BC-86EF-4082-A27D-572803716674Q38798592-BEDD2D3E-F8FB-4D88-8C21-010D991AE7F9Q39033643-078B8DBC-A178-4223-BFB0-88E8B86EC8F6Q39207518-ECF8DEB1-A09B-40A2-87CB-A83F0370EF9EQ39450920-BB0D9A90-8ED8-4A91-8DB6-1E34769716BBQ40477245-B3A0F616-D2A1-4ED0-BFA6-2471AEF7DF0BQ41073591-B592798B-7D57-4807-9374-BE6275954283Q41932390-403F1AE9-B864-49B0-B287-C52ABAFB0360Q42696818-0B85A4E9-2C8B-4A03-A379-D25A8F5861CEQ45823744-A15BBF77-A25C-4CB3-825E-7EA5B740B40EQ47678335-BC9046C7-02AD-451E-AB5A-F099E83F3710Q47767309-568A7DE2-D406-4E35-80F1-626AC60B1689Q49616059-35D4B25C-286F-426A-8C69-86DA70EA9380Q49616077-44BD3948-749B-4DF3-A1D3-20208FFDC671Q52945637-AD7062A6-886F-4A90-86F6-70940F205B44Q53215253-7A32C99E-98A5-49DB-AF06-F1DBBE046254Q54198793-BC445255-01F8-46B4-96BE-E6989676CBF1Q55008388-008C55A2-21F5-47A0-8133-168473366CB4Q55220842-293B6119-9E04-4277-BA99-830948B06228Q57076765-50577429-D36F-4331-8AEE-B357BC6B7CE4Q58129718-3A66495B-E59A-457F-AF92-AE87DEBA533CQ58733278-E4E27DCE-495A-435C-A762-1F298A2E451C
P2860
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Tophaceous gout and high level ...... rtality in patients with gout.
@en
Tophaceous gout and high level ...... rtality in patients with gout.
@nl
type
label
Tophaceous gout and high level ...... rtality in patients with gout.
@en
Tophaceous gout and high level ...... rtality in patients with gout.
@nl
prefLabel
Tophaceous gout and high level ...... rtality in patients with gout.
@en
Tophaceous gout and high level ...... rtality in patients with gout.
@nl
P2093
P2860
P50
P1476
Tophaceous gout and high level ...... ortality in patients with gout
@en
P2093
Ana Maria Herrero-Beites
Eswar Krishnan
Jose Ignacio Pijoan
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202421
P407
P577
2013-01-12T00:00:00Z